Impact of the bundled end-stage renal disease payment system on patient care

Blood Purification

Volumn 33, Issue 1-3, 2012, Pages 107-111

  Maddux, Franklin W ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

Author keywords

Dialysis; End stage renal disease; Prospective payment system; Quality incentive program

Indexed keywords

CLINICAL PRACTICE; COMORBIDITY; CONFERENCE PAPER; DIALYSIS; ERYTHROPOIESIS; HEALTH CARE COST; HUMAN; KIDNEY FAILURE; NEPHROLOGIST; OUTPATIENT CARE; PATIENT CARE; PERSONNEL MANAGEMENT; PRIORITY JOURNAL; PROSPECTIVE PAYMENT;

ANEMIA; HUMANS; KIDNEY FAILURE, CHRONIC; PROSPECTIVE PAYMENT SYSTEM; RENAL DIALYSIS;

EID: 84856052733     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000334164     Document Type: Conference Paper

References (7)

1. Medicare Payment Advisory Commission (MedPAC): Report to the Congress: Medicare payment policy, March 2001 Centers for Medicare and Medicaid Services: End stage renal disease (ESRD) payment. http://www.cms.gov/ESRDPayment/(accessed August 31, 2011).
2. Rettig R: Implementing the End Stage Renal Disease Program of Medicare (report). Arlington, RAND, 1980.
3. Lacson E, Hakim R: The 2011 ESRD prospective payment system: perspectives from Fresenius Medical Care, a large dialysis or-ga nization. Am J K idney Dis 2011; 57: 547-549.
4. Iglehart J: Bundled payment for ESRD-including ESAs in Medicare's dialysis package. N Engl J Med 2011; 364:593-595.
5. Lacson E, Brunelli S: Hemodialysis treatment time: a fresh perspective. Clin J Am Soc Nephrol 2011; 6:2522-2530.
6. Food and Drug Administration: Information on erythropoiesis-stimulating agents (ESA) epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Ara nesp). http://w w w.fda.gov/d r ugs/dr ug-safety/ postmarketdrugsafetyinformation-forpatientsandproviders/ucm109375.htm (accessed August 31, 2011).
7. Delva O: How CROWNWeb will validate and utilize patient data. Nephrol News Issues 2010; 24: 30-33.